(HealthDay)—Venetoclax (VENCLEXTA) has been approved to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, the U.S. Food and Drug Administration announced yesterday.
May 17, 2019
0
1
(HealthDay)—For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online ...
Apr 16, 2019
0
1
Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival. Yet quiescent leukemic stem cells persist ...
Mar 21, 2019
0
6
In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.
Feb 6, 2019
0
0
Many new anti-cancer drugs inhibit proteins that are essential for the proliferation of cancer cells. One example is ibrutinib, an innovative therapy for chronic lymphocytic leukemia first approved in 2014. Chronic lymphocytic ...
Jan 29, 2019
0
18
Results from an multi-institutional, phase 3 clinical trial show that older patients with chronic lymphocytic leukemia (CLL) have a significantly lower rate of disease progression if treated with the newer targeted drug, ...
Dec 3, 2018
0
25
Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management. Joint recommendations on diagnosis ...
Nov 30, 2018
0
2
A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer Center, reports an investigational drug called tagraxofusp has demonstrated high response rates in patients with blastic plasmacytoid ...
Nov 14, 2018
0
3
For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published today in the journal Blood.
Oct 4, 2018
0
1
A single leukemia cell, unknowingly engineered with the leukemia-targeting chimeric antigen receptor (CAR) lentivirus and infused back into a patient, was able to reproduce and cause a deadly recurrence of B-cell acute lymphoblastic ...
Oct 1, 2018
0
20
